These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 16489047

  • 1. Molecular target-based therapy of pancreatic cancer.
    Lebedeva IV, Sarkar D, Su ZZ, Gopalkrishnan RV, Athar M, Randolph A, Valerie K, Dent P, Fisher PB.
    Cancer Res; 2006 Feb 15; 66(4):2403-13. PubMed ID: 16489047
    [Abstract] [Full Text] [Related]

  • 2. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
    Lebedeva IV, Su ZZ, Sarkar D, Gopalkrishnan RV, Waxman S, Yacoub A, Dent P, Fisher PB.
    Oncogene; 2005 Jan 20; 24(4):585-96. PubMed ID: 15580305
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
    Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW.
    Cancer Res; 2006 Oct 01; 66(19):9736-43. PubMed ID: 17018633
    [Abstract] [Full Text] [Related]

  • 4. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells.
    Lebedeva IV, Su ZZ, Emdad L, Kolomeyer A, Sarkar D, Kitada S, Waxman S, Reed JC, Fisher PB.
    Oncogene; 2007 Feb 01; 26(5):733-44. PubMed ID: 16924242
    [Abstract] [Full Text] [Related]

  • 5. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.
    Hatanaka K, Suzuki K, Miura Y, Yoshida K, Ohnami S, Kitade Y, Yoshida T, Aoki K.
    J Gene Med; 2004 Oct 01; 6(10):1139-48. PubMed ID: 15452878
    [Abstract] [Full Text] [Related]

  • 6. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity.
    Miura Y, Ohnami S, Yoshida K, Ohashi M, Nakano M, Ohnami S, Fukuhara M, Yanagi K, Matsushita A, Uchida E, Asaka M, Yoshida T, Aoki K.
    Cancer Lett; 2005 Jan 31; 218(1):53-62. PubMed ID: 15639340
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
    Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA.
    Mol Cancer Res; 2005 Jul 31; 3(7):413-23. PubMed ID: 16046552
    [Abstract] [Full Text] [Related]

  • 10. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K, Park S, Ewton DZ, Friedman E.
    Cancer Res; 2007 Aug 01; 67(15):7247-55. PubMed ID: 17671193
    [Abstract] [Full Text] [Related]

  • 11. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.
    Shi XH, Liang ZY, Ren XY, Liu TH.
    Cancer Gene Ther; 2009 Mar 01; 16(3):227-36. PubMed ID: 18949011
    [Abstract] [Full Text] [Related]

  • 12. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
    Hirokawa Y, Levitzki A, Lessene G, Baell J, Xiao Y, Zhu H, Maruta H.
    Cancer Lett; 2007 Jan 08; 245(1-2):242-51. PubMed ID: 16540233
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J, Ouyang ZG, Zhang SH, Zhen YS.
    Oncol Rep; 2007 Jun 08; 17(6):1445-51. PubMed ID: 17487403
    [Abstract] [Full Text] [Related]

  • 14. Effect of recombinant adenovirus vector mediated human interleukin-24 gene transfection on pancreatic carcinoma growth.
    Pan XT, Zhu QY, Li DC, Yang JC, Zhang ZX, Zhu XG, Zhao H.
    Chin Med J (Engl); 2008 Oct 20; 121(20):2031-6. PubMed ID: 19080270
    [Abstract] [Full Text] [Related]

  • 15. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B, He Y, Sun DL, Zou Y, Qin XH, Huang BH.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 22; 88(28):1956-60. PubMed ID: 19062734
    [Abstract] [Full Text] [Related]

  • 16. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.
    Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N.
    Gene Ther; 2000 Mar 22; 7(6):518-26. PubMed ID: 10757026
    [Abstract] [Full Text] [Related]

  • 17. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice.
    Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K, Fisher PB.
    Cancer Res; 2005 Oct 01; 65(19):9056-63. PubMed ID: 16204080
    [Abstract] [Full Text] [Related]

  • 18. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
    Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ.
    Cancer Res; 2007 Mar 01; 67(5):2098-106. PubMed ID: 17332339
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
    Nakano M, Aoki K, Matsumoto N, Ohnami S, Hatanaka K, Hibi T, Terada M, Yoshida T.
    Mol Ther; 2001 Apr 01; 3(4):491-9. PubMed ID: 11319909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.